← All trials
NCT04351555
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2020
- Primary completion
- Jan 19, 2024
- Completion date
- Jan 23, 2029
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 351
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- National Cancer Center, JapanOverall official - principal investigator
- Krankenhaus Bethanien gGmbHOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.